ERS Genomics
ERS Genomics is a Dublin-based intellectual property licensing company that grants non-exclusive access to the foundational CVC CRISPR/Cas9 patent portfolio to pharmaceutical, life sciences, agricultural, and synthetic biology organizations worldwide.
- Company typePrivate
- Founded2014
- HeadquartersDublin, Ireland
- Headcount1–10
- GTM typeB2B
- OfferingServices
What ERS Genomics does
ERS Genomics Limited is a Dublin-based, privately held intellectual property licensing company founded in 2014 to commercialize the foundational CRISPR/Cas9 patent estate co-owned by Nobel Laureate Prof. Emmanuelle Charpentier and her collaborators across Carnegie Institution, UC Berkeley, and the University of Vienna (the CVC portfolio). The company holds rights to 100+ granted patents spanning the United States, Europe, Japan, and China, covering compositions and methods for guiding Cas9 to target DNA in all cell types, including mammalian, bacterial, plant, and fungal systems, as well as Cas9 variants supporting CRISPRi, CRISPRa, and base editing applications. ERS exclusively licenses all fields outside of direct human gene and cell therapies, with an exclusive sublicense arrangement with Corteva Agriscience covering all agricultural crops.
The company monetizes the CVC estate through a three-tier non-exclusive licensing structure: a Standard License for established organizations covering internal research, commercial products, services, and an optional bioproduction add-on; an Express License for small teams under 15 employees and under $10M in funding, priced at $15,000 signature fee and $15,000 annual maintenance over a five-year term; and an Early Access Express License launched in February 2026 for pre-seed innovators under $1M in funding. Distribution combines a dedicated licensing team, an online self-serve portal, and regional business development consultants in North America, the UK, and India.
ERS serves more than 160 licensees globally across BioPharma, Life Science Tools, Animal Health, Plants, and Synthetic Biology, with named enterprise customers including GSK, Merck, Bayer, Thermo Fisher Scientific, Danaher, PerkinElmer, Charles River Laboratories, Corteva Agriscience, and Cargill. The company is governed by a Board chaired by co-founder Shaun Foy, with co-founders Prof. Charpentier and Dr. Rodger Novak, and is led day-to-day by CEO John E. Milad, supported by a lean executive team including a VP of Finance, General Counsel, Head of Commercial Operations, and regional BD leadership.
ERS Genomics firmographics
Firmographics- Name
- ERS Genomics
- Legal name
- ERS Genomics Limited
- Website
- https://ersgenomics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ERS Genomics is a Dublin-based intellectual property licensing company that grants non-exclusive access to the foundational CVC CRISPR/Cas9 patent portfolio to pharmaceutical, life sciences, agricultural, and synthetic biology organizations worldwide.
- Ownership category
- akta.pro rank
ERS Genomics industry classification
Industry- Product category
- Biotechnology Intellectual Property Licensing
- NAICS
- Lessors of Nonfinancial Intangible Assets (except Copyrighted Works) (533), Lessors of Nonfinancial Intangible Assets (except Copyrighted Works) (533110), Lessors of Nonfinancial Intangible Assets (except Copyrighted Works) (53311)
- SIC
- Patent Owners & Lessors (6794)
- akta.pro primary industry
- Patent Prosecution & Portfolio Management (BPAHAMAA)
Keywords
Where ERS Genomics is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices1 record
Markets served
ERS Genomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- CRISPR/Cas9 IP Licensing: ERS Genomics generates revenue through licensing its foundational CRISPR/Cas9 patent portfolio. The company offers multiple license tiers including Standard License for established organizations, Express License for small teams (under 15 employees, under $10M funding), and Early Access Express License for pre-seed startups. Revenue comes from one-time signature fees and ongoing annual maintenance fees.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Standard License for established organizations |
| Subscription | Annual | Express License for small teams |
| Subscription | Annual | Early Access Express License for pre-seed startups |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
ERS Genomics product offering
Product offeringCore offering
ERS Genomics licenses the foundational CVC CRISPR/Cas9 intellectual property portfolio — derived from Nobel Prize-winning research by Prof. Emmanuelle Charpentier — to organizations worldwide for use across BioPharma, Life Science Tools, Animals, Plants, and Synthetic Biology. The company offers tiered non-exclusive licenses (Standard, Express, and Early Access Express) that grant freedom to operate for CRISPR/Cas9 research and commercial applications outside direct human therapeutics. Revenue is generated through one-time signature fees and recurring annual maintenance fees.
Product overview
ERS Genomics operates as a CRISPR/Cas9 intellectual property licensing company offering access to the CVC Patent Portfolio — the foundational CRISPR/Cas9 patent estate derived from Nobel Prize-winning research by Prof. Emmanuelle Charpentier. The company offers a tiered licensing structure: the Standard License for established organizations covering internal research, commercial products, services, and optional bioproduction; the Express License for small startups under 15 employees and under $10M in funding at $15,000/year for internal research use; and the Early Access Express License — a reduced-cost entry point for pre-seed innovators under $1M in funding for up to three years. All licenses are non-exclusive and cover CRISPR/Cas9 applications across BioPharma, Life Science Tools, Animals, Plants, and Synthetic Biology fields worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- CVC Patent Portfolio (Foundational CRISPR/Cas9 IP) The foundational CRISPR/Cas9 intellectual property estate co-owned by Nobel Laureate Prof. Emmanuelle Charpentier, covering core gene-editing methods and compositions across all cell types including mammalian, bacterial, plant, and fungal systems. Provides freedom to operate for organizations using CRISPR/Cas9 in research and commercial applications outside direct human therapeutics.
- Standard License Comprehensive licensing for established organizations requiring internal research use rights and commercial product or service offerings, with optional bioproduction add-on. Includes dedicated licensing support from the ERS licensing team.
- Express License Non-exclusive worldwide license for internal research use of CRISPR/Cas9 for small organizations. Available to companies under 15 employees, under USD 10M in funding, and less than 5 years old. One-time signature fee of $15,000 USD, annual maintenance fee of $15,000 USD, 5-year term.
- Early Access Express License Reduced-cost entry point for pre-seed, pre-revenue stage innovators, providing a subset of Express License rights. Designed for companies with less than $1M in funding. Offers substantially reduced upfront and annual fees for up to three years, automatically converting to full Express License terms.
Quantifiable outcome
- 160+ organizations worldwide have secured their Freedom to Operate with foundational CRISPR/Cas9 IP from ERS Genomics
- +2 more outcomes
Companies that use ERS Genomics
Customer profileNamed customers14 records
Segments5 records
Ideal customer profiles5 records
ERS Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
ERS Genomics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and flagship.
- Aurigene Pharmaceutical Services LimitedcoreERS Genomics signed a non-exclusive license agreement with Aurigene Pharmaceutical Services Limited, granting access to its foundational CRISPR/Cas9 patent portfolio. The agreement enables Aurigene to integrate precision genome editing capabilities into its drug discovery platforms, supporting global pharmaceutical and biotechnology partners across small molecule and biologics programs. Aurigene is a subsidiary of Dr. Reddy's Laboratories and operates as an end-to-end integrated CRDMO.
- Dyadic Applied BioSolutionscoreNon-exclusive license agreement enabling Dyadic to accelerate strain engineering and pathway optimization to enhance productivity, product quality, and innovation across its proprietary bioproduction platforms. The license supports both Dyadic's internal product pipeline and the customized production strains developed for partners across life sciences, food and nutrition, and bio-industrial sectors.
- Jumpcode GenomicscoreNon-exclusive CRISPR/Cas9 license agreement providing Jumpcode access to ERS' patent portfolio to enhance next-generation sequencing capabilities. The partnership empowers Jumpcode to advance sensitivity and efficiency of NGS and expand applications across multiple research and clinical areas including basic research, infectious disease detection, molecular diagnostics, and oncology.
- Corteva AgriscienceflagshipExclusive sublicense arrangement for plant agriculture. Corteva (previously DowDuPont and Pioneer) holds exclusive rights for commercial and sub-licensing rights for CRISPR/Cas9 use in all agricultural crops. Corteva is the world's leading developer and supplier of advanced plant genetics, providing seeds to farmers in more than 90 countries.
- Bioneer A/ScoreLicensee case study partner using CRISPR/Cas9 for advanced disease modelling, assay development, and drug discovery services. Bioneer operates a 3,350-square-meter facility in Hørsholm, Denmark, and uses CRISPR for creating genetically modified cell lines, reporter cell lines, and inducible gene expression systems for neurological disease research.
Scale indicators4 records
Recent moves6 records
Expansion highlights8 records
ERS Genomics competitors and assessment
Company assessmentBroad incumbents
- Intellia Therapeutics: Clinical-stage in-vivo CRISPR/Cas9 developer (using Charpentier/Doudna foundational IP). Comparable as a deep CRISPR therapeutics developer that depends on the type of foundational IP ERS licenses, and representative of the cell and gene therapy market ERS is structurally excluded from.
- Editas Medicine: CRISPR-based gene editing company originally licensed under the Broad Institute portfolio. It provides a useful comparable for how foundational CRISPR IP translates into a therapeutic pipeline and the licensing economics that support it.
- CRISPR Therapeutics: Clinical-stage gene editing company co-founded by Emmanuelle Charpentier that developed CASGEVY (the first FDA-approved CRISPR therapy) in partnership with Vertex. While it operates in the therapeutic field ERS is excluded from, it is a foundational CRISPR company and an important reference point for the value of CVC IP.
Emerging players
- Mammoth Biosciences: CRISPR-based diagnostics and gene editing company co-founded by Jennifer Doudna. Comparable as a CRISPR platform player addressing the same set of life sciences, agricultural, and industrial customers that ERS licenses, and representative of the broader Doudna/Charpentier IP ecosystem.
- Beam Therapeutics: Pioneer of base editing — a direct application covered by ERS's CVC IP for nCas9/base editing variants. Beam is a relevant comparable for the next-generation editing applications that ERS's Cas9 variant patents (nCas9, dCas9) enable.
- Synthego: Provider of CRISPR tools, reagents, and cell engineering services to researchers and commercial customers — directly comparable as an ERS licensee segment (Life Science Tools) and a key customer type for ERS's Express and Standard licensing programs.
- Caribou Biosciences: CRISPR genome editing company (originally spun out of Doudna lab) developing both therapeutic and non-therapeutic applications. Comparable as a CRISPR platform company that both uses and depends on foundational IP similar to ERS's CVC portfolio.
Direct peers
- Broad Institute: Holds foundational competing CRISPR/Cas9 patent claims (Zhang lab) and is the principal IP adversary in the CVC interference. Both Broad and ERS license Cas9 IP to the global research and commercial market, with overlapping customer rosters across pharma, life sciences, and agriculture.
- ToolGen: Korean biotechnology company that holds independent foundational CRISPR/Cas9 IP and licenses it to global research and commercial users. It is one of the few direct IP-level peers to ERS in the CRISPR licensing market.
Others
- MPEG LA: Independent licensing administrator that aggregates and licenses patent pools across technology categories. Comparable as a structural peer in the IP licensing business model, particularly relevant to understanding how a single-purpose patent licensing entity with 100+ granted patents and 100+ licensees is valued and operated.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
ERS Genomics social profiles
Digital presenceERS Genomics compliance and trust
Trust signalCompliance1 record
ERS Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ERS Genomics leadership team
Management profileNumber of profiles
Profiles11 records
ERS Genomics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ERS Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ERS Genomics
What does ERS Genomics do?
ERS Genomics licenses the foundational CVC CRISPR/Cas9 intellectual property portfolio — derived from Nobel Prize-winning research by Prof. Emmanuelle Charpentier — to organizations worldwide for use across BioPharma, Life Science Tools, Animals, Plants, and Synthetic Biology. The company offers tiered non-exclusive licenses (Standard, Express, and Early Access Express) that grant freedom to operate for CRISPR/Cas9 research and commercial applications outside direct human therapeutics. Revenue is generated through one-time signature fees and recurring annual maintenance fees.
Is ERS Genomics a public or private company?
ERS Genomics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ERS Genomics founded?
ERS Genomics was founded in 2014. It employs 1 to 10 people.
Where is ERS Genomics based?
ERS Genomics is headquartered in Dublin, Ireland, in the Europe region.
How does ERS Genomics make money?
One revenue line is on record: CRISPR/Cas9 IP Licensing.
Who are ERS Genomics's main competitors?
Broad incumbents on record are Intellia Therapeutics, Editas Medicine and CRISPR Therapeutics. Emerging players are Mammoth Biosciences, Beam Therapeutics, Synthego and Caribou Biosciences. Direct peers are Broad Institute and ToolGen. MPEG LA is listed as an others.
Does ERS Genomics have an API?
No public API is recorded for ERS Genomics.
What industry is ERS Genomics in?
ERS Genomics's product category is Biotechnology Intellectual Property Licensing. Its primary akta.pro industry code is BPAHAMAA, Patent Prosecution & Portfolio Management. Its NAICS code is 533 and its SIC code is 6794.